ホームページへ
4.6/5
TrustPilot

ページ2 - トルコで最高の膵神経内分泌腫瘍医師 - トップ41名の医師

トルコのトップ膵神経内分泌腫瘍医師と価格を比較。こちらで最適なマッチングを見つけてください

トルコの3名のトップ専門家から見積もりを取得

ご要望と予算に基づいて最適な医師を厳選いたします

トップ医師

41

トルコ

レビュー

14000+

実際の患者より

個別化された治療計画を無料で取得し、最良のオプションを選択してください。コミットメント不要 · サービス料金なし

Medipol Mega University Hospital
Ozcan Yildiz

Ozcan Yildiz

76年の経験
クリニックは認証済み
Joint Commission International
Patient choice in Pediatric Oncology & Hematology Oncology
所在地: トルコ, イスタンブール
Dr. Yildiz has published numerous articles in international peer-reviewed journals, examining topics such as Gastroenteropancreatic neuroendocrine tumors, lipid-lowering treatment, dexamethasone suppression tests, thyroxin therapy, familial Mediterranean fever, and idiopathic thrombocytopenia. These articles have been published in journals such as Medical Oncology, J Endocrinol Invest, Swiss Med Wkly, Int J Cardiol, Eur J Med Res, Ethiop Med J, Gynecol Oncol, Med Hypotheses, Int J Gynecol Cancer, Med Oncol, West Indian Med J, and Cases J.
パッケージ価格$6,000
Istinye University Liv Hospital Bahcesehir
Tahsin Ozatli

Tahsin Ozatli

2016年の経験
クリニックは認証済み
Best clinic for radiotherapy
Best price for PET/CT
Turkish Medical Association
所在地: トルコ, イスタンブール

この医師は、乳がん、肺がん、消化器系がんの治療を専門とする腫瘍学者です。現在、医師はIstinye Liv University Hospitalで診療を行っています。<\/p>

多くの著名な機関でのキャリアを持ち、医師はMalatya State Hospitalで内科専門医として、Ankara Oncology Clinicで医師として、Erzurum Regional Training and Research Hospitalの腫瘍学部門のメンバーとして勤務してきました。<\/p>

医師はSelcuk Universityの医学部を卒業し、2016年に准教授の称号を取得しました。<\/p>

診察お問い合わせください
Medipol Acibadem District Hospital
Gul Alco

Gul Alco

31年の経験
クリニックは認証済み
Joint Commission International
所在地: トルコ, イスタンブール

Education

  • 1986-1989, Bursa High School, Bursa, Turkey
  • 1989-1995, Istanbul University, Istanbul School of Medicine, Turkey
  • 1999-2003, (Residency) Kadir Has University, School of Medicine, Department of Radiation Oncology, Istanbul, Turkey
  • 2015, (Associate Professor) Demiroglu Bilim University, Department of Radiation Oncology, Istanbul, Turkey
  • 2021, (Professor) Demiroglu Bilim University, Department of Radiation Oncology, Istanbul, Turkey
  • 2024, Istanbul Medipol University, Department of Radiation Oncology, Istanbul, Turkey

Experience

  • 1995-1999, Şişli Florence Nightingale Hospital, Istanbul, Cardiology Department
  • 2003, Gayrettepe Florence Nightingale Hospital, Istanbul, Department of Radiation Oncology
  • 2015, (Associate Professor in Radiation Oncology) Demiroglu Bilim University, Department of Radiation Oncology, Istanbul, Turkey
  • 2021, (Professor in Radiation Oncology) Demiroglu Bilim University, Department of Radiation Oncology, Istanbul, Turkey
  • 2024, Istanbul Medipol University, Department of Radiation Oncology, Istanbul, Turkey
診察お問い合わせください
Büyük Anadolu Hospitals (BAH International)
Muzaffer Al

Muzaffer Al

16年の経験
クリニックは認証済み
Turkish Medical Association
International Health Tourism Authorization Certificate
Turkish Medical Association (Türk Tabıplerı Bırliği)
所在地: トルコ, イスタンブール

Education

 

Ondokuz Mayıs University Faculty of Medicine (1991)

KTÜ Faculty of Medicine Farabi Hospital (Specialization.1998)

Istanbul University Çapa Faculty of Medicine (Laparoscopic Surgery Training, 2002)

Istanbul University Çapa Faculty of Medicine (Laparoscopic Antireflux Surgery Training, 2006)

Istanbul University Cerrahpaşa Faculty of Medicine (General Surgery Clinic Advance Laparoscopic Surgery, Laparoscopic Bariatric Surgery, Morbid Obesity and Oncological Cancer Surgery Training, 2010i)

 

 

 

 

診察お問い合わせください
Medical Park Antalya Hospital Complex
Mustafa Serkan Alemdar

Mustafa Serkan Alemdar

20年の経験
クリニックは認証済み
International Health Tourism Authorization Certificate
所在地: トルコ, アンタルヤ

Education and Specialization

  • 2006: Kocaeli University Faculty of Medicine
  • 2014: Akdeniz University Faculty of Medicine, Internal Medicine
  • 2018: Akdeniz University Faculty of Medicine, Medical Oncology

Experience

  • 2006 - 2008: Konya Derebucak District Hospital
  • 2009 - 2015: Akdeniz University Hospital
  • 2015: Antalya Kaş State Hospital
  • 2015 - 2016: İnönü University Faculty of Medicine
  • 2016 - 2021: Akdeniz University Hospital
  • 2021 - 2023: Antalya Training and Research Hospital
診察お問い合わせください
Medipol Bahçelievler Hospital
Nail Paksoy

Nail Paksoy

15年の経験
クリニックは認証済み
Joint Commission International
所在地: トルコ, イスタンブール
クリニック:
4.5
Medipol Bahçelievler Hospital


PROFESSIONAL EXPERIENCE

2011-2012
Erzurum Koprukoyu State Hospital
Department: General Medicine

2012-2017
Istanbul University Cerrahpaşa Medical Faculty
Department: Internal Medicine

06/2017-10/2017
Istanbul Gaziosmanpasa Taksim Training and Research Hospital
Department: Internal Medicine

10/2017-11/2018
Istanbul University Istanbul Medical Faculty
Department: Allergy and Immunology Fellowship

2018/2022
Istanbul University Oncology Institute
Department: Medical Oncology Fellowship

2022-2023
Tekirdag City Hospital
Department: Medical Oncology Specialist

2023-present
Istanbul Medipol University Medipol Bahcelievler Private Hospital
Department: Medical Oncology Assoc. Prof.

 

EDUCATION

2005-2011
Medical Education
Sivas Cumhuriyet University Medical Faculty, Sivas, Turkey

2012-2017
Internal Medicine
Istanbul University Cerrahpaşa Medical Faculty, Department of Internal Medicine, Istanbul, Turkey

2017-2018
Allergy-Immunology Fellowship
Istanbul University Istanbul Medical Faculty
Department of Internal Medicine, Division of Allergy and Immunology, Istanbul, Turkey

2018-2022
Medical Oncology Fellowship
Istanbul University Oncology Institute, Department of Medical Oncology, Istanbul, Turkey

2022
ESMO Board Certification in Medical Oncology
10th September 2022 in Paris, France.

2023
Medical Oncology Assoc. Prof.
Istanbul Medipol University Department of Medical Oncology, Istanbul, Turkey

 

INTERNATIONAL CLINICAL TRIALS:

1. Astefania - ROCHE

  • Title: A Study Evaluating the Efficacy and Safety of Adjuvant Atezolizumab or Placebo and Trastuzumab Emtansine for Participants With HER2-Positive Breast Cancer at High Risk of Recurrence Following Preoperative Therapy
  • Role: Subinvestigator

2. PFİZER

  • Title: A Study Of Lorlatinib Versus Crizotinib In First-Line Treatment Of Patients With ALK-Positive NSCLC
  • Role: Subinvestigator

3. RECITE - AMGEN

  • Title: Study of Romiplostim for Chemotherapy-induced Thrombocytopenia in Adult Subjects With Gastrointestinal, Pancreatic, or Colorectal Cancer
  • Role: Subinvestigator

4. NAVIGATE - BAYER

  • Title: A Study to Test the Effect of the Drug Larotrectinib in Adults and Children With NTRK-fusion Positive Solid Tumors
  • Role: Subinvestigator

5. RUBY - Tesaro (PRA)

  • Title: A Phase 3, Randomized, Double-blind, Multicenter Study of Dostarlimab (TSR-042) Plus Carboplatin-paclitaxel Versus Placebo Plus Carboplatin-paclitaxel in Patients With Recurrent or Primary Advanced Endometrial Cancer
  • Role: Subinvestigator

6. ENGOT-ov43/GOG-3036 - MSD

  • Title: Study of Chemotherapy With Pembrolizumab (MK-3475) Followed by Maintenance With Olaparib (MK-7339) for the First-Line Treatment of Women With BRCA Non-mutated Advanced Epithelial Ovarian Cancer (EOC) (MK-7339-001/KEYLYNK001/ENGOT-ov43/GOG-3036)
  • Role: Subinvestigator

7. ASTRA ZENECA

  • Title: To Study Clinical Effectiveness and Safety of Olaparib Monotherapy in Metastatic Breast Cancer Patients.
  • Role: Subinvestigator

8. ROSY-O - ASTRA ZENECA

  • Title: Roll Over StudY for Patients Who Have Completed a Previous Oncology Study With Olaparib
  • Role: Subinvestigator
  •  

INTERNATIONAL PUBLICATIONS

I. Published journal articles indexed by SCI, SSCI, and AHCI

Weekly Paclitaxel in Classic Kaposi Sarcoma

  • Authors: Paksoy, N., Khanmammadov, N., Doğan, İ., Ferhatoğlu, F., Ahmed, M. A., Karaman, S., & Aydiner, A.
  • Journal: Medicine, 102(5)

Carboplatin Desensitization in Ovarian Carcinoma

  • Authors: Paksoy, N., Khanmammadov, N., Doğan, İ., Ferhatoğlu, F., Yildiz, A., Ak, N., & Aydiner, A.
  • Journal: Medicine, 101(45), e31726

High-Dose Chemotherapy for Ewing’s Sarcoma

  • Authors: Paksoy, N., Ferhatoglu, F., Dogan, İ., Khanmammadov, N., Celik, A. I., Gulbas, Z., & Başaran, M.
  • Journal: Medicine, 101(49), e32213

Multidrug Refractory TFE3(+) Renal Cell Carcinoma

  • Authors: Paksoy, Nail, et al.
  • Journal: Journal of Oncology Pharmacy Practice, 2022, 28.1: 215-221

Crizotinib Efficacy in NSCLC with MET Alterations

  • Authors: Gürbüz, M., Kiliçkap, S., Bilici, A., Karadurmuş, N., Sezer, A., Şendur, M. A. N., ... & Demirkazik, A.
  • Journal: Medicine, 101(50), e32368

Clinicopathological Features in ALK Mutant NSCLC

  • Authors: Dogan, I., Gurbuz, M., Paksoy, N., Ferhatoglu, F., Vatansever, S., Saip, P., ... & Aydiner, A.
  • Journal: Medicine, 101(34)

PSMA-Based Tumor Burden in Prostate Cancer

  • Authors: HAS SIMSEK, Duygu, et al.
  • Journal: Annals of Nuclear Medicine, 2021, 35.6: 680-690

Atezolizumab in Metastatic Urothelial Carcinoma

  • Authors: TURAL, Deniz, et al.
  • Journal: European Urology Focus, 2021, 7.5: 1061-1066

Pulmonary Sarcomatoid Carcinoma

  • Authors: FERHATOGLU, Ferhat, et al.
  • Journal: Oncology Research and Treatment, 2021, 44.11: 590-601

Prognostic Factors in Atezolizumab-Treated Urothelial Carcinoma

  • Authors: TURAL, Deniz, et al.
  • Journal: International Journal of Clinical Oncology, 2021, 26.8: 1506-1513

Atezolizumab with Chemotherapy in Small Cell Lung Cancer

  • Authors: GÜRBÜZ, Mustafa, et al.
  • Journal: Journal of Cancer Research and Clinical Oncology, 2022, 1-9

FOLFIRINOX vs. Gemcitabine + Nab-Paclitaxel in Pancreatic Cancer

  • Authors: AY, Seval, et al.
  • Journal: Journal of Chemotherapy, 2022, 1-7

Trastuzumab Emtansine in Older HER2-Positive Breast Cancer Patients

  • Authors: CIL, Ibrahim, et al.
  • Journal: Tumori Journal, 2022, 108.1: 19-25

Real-Life Efficacy of Osimertinib in Advanced NSCLC

  • Authors: HIZAL, Mutlu, et al.
  • Journal: Journal of Cancer Research and Clinical Oncology, 2022, 148.6: 1501-1508

ALK-Positive Cells Percentage and Alectinib Efficacy

  • Authors: Hizal, M., Bilgin, B., Paksoy, N., Atcı, M. M., Kahraman, S., Kılıçkap, S., ... & Şendur, M. A. N.
  • Journal: Journal of Cancer Research and Clinical Oncology, 149(8), 4141-4148

Real-World Data on Alectinib in ALK-Positive NSCLC

  • Authors: Hizal, M., Bilgin, B., Paksoy, N., Kılıçkap, S., Atcı, M. M., Kahraman, S., ... & Şendur, M. A. N.
  • Journal: Future Oncology, 18(23), 2573-2582

Prognostic Factors in Metastatic RCC with T790M Mutation

  • Authors: Dogan, I., Iribas, A., Paksoy, N., Vatansever, S., & Basaran, M.
  • Journal: Journal of Cancer Research and Therapeutics

FLOT Regimen in Metastatic Gastric Cancer

  • Authors: Tastekin, D., Paksoy, N., Dogan, I., Ferhatoglu, F., Khanmammadov, N., Bozbey, H. U., & Karabulut, S.
  • Journal: Journal of Cancer Research and Therapeutics

Desensitization Protocol in Lenalidomide Hypersensitivity Reactions

  • Authors: DEMIR, Semra, et al.
  • Journal: Annals of Allergy, Asthma & Immunology, 2019, 123.4: 394-397

Factors Associated with Diagnostic Skin Test Positivity in PPI Hypersensitivity

  • Authors: ÖZDEMIR, Seçil Kepil, et al.
  • Journal: Allergy, 2019, 74.6: 1187-1190

Efficacy of Capecitabine and Temozolomide in Neuroendocrine Tumors

  • Authors: Ünal, Ç., Azizy, A., Karabulut, S., Taştekin, D., Akyıldız, A., Yaşar, S., ... & Sağlam, S.
  • Journal: The Oncologist, oyad257

Subsequent Treatments in Hormone-Positive Breast Cancer Progression

  • Authors: Karacin, C., Oksuzoglu, B., Demirci, A., Keskinkılıç, M., Baytemür, N. K., Yılmaz, F., ... & Hacıbekiroğlu, İ.
  • Journal: BMC cancer, 23(1), 192

Termination of Trastuzumab in HER2-Positive Metastatic Breast Cancer

  • Authors: Dogan, I., Aydin, E., Khanmammadov, N., Paksoy, N., Saip, P., & Aydiner, A.
  • Journal: Scientific Reports, 13(1), 8779

Long-term Outcomes and Predictors of Recurrence in Node-Negative Early Stage Breast Cancer

  • Authors: Dogan, I., Aydin, E., Khanmammadov, N., Paksoy, N., Ferhatoğlu, F., Ak, N., ... & Aydiner, A.
  • Journal: Journal of Cancer Research and Clinical Oncology, 1-9

Prognostic Factors Influencing PFS in HER2-Positive Metastatic Breast Cancer

  • Authors: Doğan, İ., Paksoy, N., Ak, N., Vatansever, S., Saip, P., & Aydıner, A.
  • Journal: European Journal of Breast Health, 19(2), 128

Treatment Efficacy of Ribociclib or Palbociclib plus Letrozole in Metastatic Breast Cancer

  • Authors: Kahraman, S., Erul, E., Seyyar, M., Gumusay, O., Bayram, E., Demirel, B. C., ... & Nahit Sendur, M. A.
  • Journal: Future Oncology, 19(10), 727-736

Efficacy and Safety of Sorafenib in Adult Metastatic Osteosarcoma Patients

  • Authors: Dogan, I., Paksoy, N., & Basaran, M.
  • Journal: Journal of Cancer Research and Therapeutics

Single-Agent Temozolomide as Salvage Therapy in Heavily Pretreated Metastatic Sarcoma Patients

  • Authors: Dogan, I., Paksoy, N., & Basaran, M.
  • Journal: Journal of Cancer Research and Therapeutics

Outcomes and Prognostic Factors in Metastatic Renal Cell Carcinoma with Brain Metastases

  • Authors: Dogan, I., Iribas, A., Paksoy, N., Vatansever, S., & Basaran, M.
  • Journal: Journal of Cancer Research and Therapeutics

FLOT Regimen in First-Line Treatment of Metastatic Gastric Cancer

  • Authors: Tastekin, D., Paksoy, N., Dogan, I., Ferhatoglu, F., Khanmammadov, N., Bozbey, H. U., & Karabulut, S.
  • Journal: Journal of Cancer Research and Therapeutics

Prognostic Factors of Perioperative FLOT Regimen in Operable Gastric Cancer

  • Authors: Erol, C., Sakin, A., Basoglu, T., Ozden, E., Cabuk, D., Dogan, M., ... & Sendur, M. A. N.
  • Journal: [Not specified]

Efficacy and Outcomes of Systemic Chemotherapy in Posttransplant Kaposi Sarcoma

  • Authors: Khanmammadov, N., Paksoy, N., Doğan, I., Ferhatoğlu, F., Saip, P., & Aydiner, A.
  • Journal: Medicine, 102(39), e35383

Comparison of Second-Line Treatments in Metastatic Renal Cell Carcinoma

  • Authors: Pehlivan, M., Paksoy, N., Aydin, E., Basaran, M., & Ekenel, M.
  • Journal: Medicine, 102(41), e35245

Toxicity Management and Effectiveness of Regorafenib in Advance GIST Patients: A Real-world Study - Authors: Paksoy, N., Ferhatoğlu, F., Doğan, İ., Khanmammadov, N., Bozbey, H. U., Karabulut, S., & Taştekin, D. - Journal: TURKISH JOURNAL OF ONCOLOGY, 1(1)

Demographic and Clinical Features and Factors Associated with Survival in Patients with Primary Glomerulonephritis: Single Tertiary Center Experience - Authors: Paksoy, N., Trabulus, S., Seyahi, N., & Altiparmak, M. R. - Journal: Namik Kemal Tip Dergisi, 11(1)

Efficacy of Sorafenib in Symptomatic Patients with Pretreated Progressive Desmoid Tumors - Authors: Paksoy, N., Ferhatoglu, F., Dogan, I., Ak, N., Pehlivan, M., Ekenel, M., & Basaran, M.

Nodal Response to Neoadjuvant Chemotherapy is a Better Predictive Factor of Survival Than Miller-Payne Scoring in Breast Cancer - Authors: Ak, Naziye, et al. - Journal: Journal of Oncological Sciences, 7.2: 42-49

Evaluation of Prognostic and Predictive Values of Hemogram Parameters in Patients with Advanced Stage Ovarian Carcinoma - Authors: Ak, Naziye, et al. - Journal: Turkish Journal of Oncology/Türk Onkoloji Dergisi, 2021, 36.4

Identifying Risk Factors Associated with Survival and Drug-Related Toxicities in Imatinib-Resistant Gastrointestinal Stromal Tumor (GIST) Patients Treated with Sunitinib - Authors: Ferhatoglu, F., Karabulut, S., Paksoy, N., & Tastekin, D.

Real-life Outcomes of ROS1 Fusion-positive Metastatic Lung Cancer Patients who were Treated with Crizotinib - Authors: Dogan, İ., Khanmammadov, N., Paksoy, N., Ferhatoglu, F., Aydın, E., Vatansever, S., & Aydine, A. - Journal: TURK ONKOLOJI DERGISI-TURKISH JOURNAL OF ONCOLOGY

Predictors of the acquisition of T790M mutation in EGFR-mutant metastatic lung cancer patients who were treated with EGFR inhibitors - Authors: Dogan, I., Khanmammadov, N., Paksoy, N., Vatansever, S., Saip, P., & Aydıner, A. - Journal: Eurasian Journal of Pulmonology

Laterality of Adrenal Gland Metastasis in Lung Cancer: Results of a Comparative Study - Authors: Ferhatoglu, F., Gagatay, T., Okumus, G., Aydiner, A., Paksoy, N., Ak, N., ... & Saip, P. - Journal: Eurasian Journal of Medical Investigation, 7(2)

Poor Risk Factors Affecting Cancer Patients Infected with Covid-19: A Retrospective Comparative Study from a Pandemic Hospital - Authors: Ferhatoglu, F., Kapağan, T., Paksoy, N., Ak, N., Medetalibeyoğlu, A., Şenkal, N., ... & Vatansever, S. - Journal: Turk Onkoloji Dergisi, 38(1)

Systemic Treatment Outcomes of Progressive Medullary Thyroid Carcinoma from the Registries of a Tertiary Cancer Center - Authors: Ferhatoglu, F., Paksoy, N., & Başaran, M. - Journal: Namik Kemal Tip Dergisi, 10(4)

Evaluation of clinical features and risk factors related to late recurrence (> 5 years) in patients with breast cancer - Authors: Ferhatoglu, F., Aydiner, A., & Paksoy, N. - Journal: Journal of Surgery & Medicine (JOSAM), 6(12)

Assessing the Clinical Impact of Lutetium-177 DOTATATE Peptide Receptor Radionuclide Therapy (PRRT) on Metastatic Neuroendocrine Tumors: A Multicenter Real-World Data from Türkiye

 

Thesis:

Istanbul University Cerrahpaşa Medical Faculty, Internal Medicine Department PAKSOY, Nail. Demographical, clinical characteristics and survival factors in patients withprimary glomerulonephritis: Cerrahpasa Medical Faculty Experience. (2016)

International Refereed Congress / Symposium Publications in Proceedings (ASCO/ESMO Abstracts)

Prognostic factors influencing progression-free survival in HER2 positive metastatic breast cancer patients who treated with lapatinib and capecitabine combination

  • Authors: Dogan, I., Paksoy, N., Ak, N., Vatansever, S., Saip, P., & Aydiner, A. (2022)

Efficacy of regorafenib and 5-fluorouracil-based rechallenge treatment in the third-line treatment of metastatic colorectal cancer: A Turkish oncology group study

  • Authors: Şenocak Taşçi, E., Oyan, B., Sonmez, O., Mutlu, A. U., Atcı, M. M., Oner, I., ... & Gulmez, A. (2022)

Long-term outcomes and predictors of recurrence in patients with early-stage node-negative breast cancer

  • Authors: Dogan, I., Aydin, E., Paksoy, N., Ferhatoglu, F., Ak, N., Ibis, K., ... & Aydiner, A. (2021)

Efficacy of temozolomide in pretreated patients with metastatic sarcoma

  • Authors: Paksoy, N., Dogan, I., Ekenel, M., & Basaran, M. (2021)

Efficacy of sorafenib in symptomatic patients with pretreated progressive desmoid tumors

  • Authors: Ferhatoglu, F., Paksoy, N., Dogan, I., Ak, N., Pehlivan, M., Ekenel, M., & Basaran, M. (2021)

Efficacy of sorafenib in heavily pretreated adult patients with metastatic osteosarcoma

  • Authors: Paksoy, N., Dogan, I., Ekenel, M., & Basaran, M. (2021)

Outcomes and prognostic factors in metastatic renal cell carcinoma patients with brain metastases

  • Authors: Dogan, İ., Iribas, A., Paksoy, N., Ekenel, M., Vatansever, S., & Basaran, M. (2021)

Association of response to first-line chemotherapy with the efficacy of atezolizumab in patients with metastatic urothelial carcinoma

  • Authors: Tural, D., Olmez, O. F., Sümbül, A. T., Artac, M., Ozhan, N., Akar, E., ... & Erman, M. (2021)

Safety and survival in adult women with platinum-sensitive relapsed BRCA mutant ovarian cancer: A study of patients in Olaparib Turkey Early Access Program—LynTurk study

  • Authors: Esin, E., Ahmed, M. A., Yıldırım, H. Ç., Mandel, N. M., Erdemoglu, E., Sari, M., ... & Paydas, S. (2023)

Atezolizumab in patients with metastatic urothelial carcinoma who have progressed after first-line chemotherapy: Results of real-life experiences

  • Authors: Tural, D., Ölmez, Ö. F., Sümbül, A. T., Artaç, M., Özhan, N., Akar, E., ... & Kılıçkap, S. (2021)

 

 

診察お問い合わせください
İstinye University Liv Hospital Topkapı
Irfan Cicin

Irfan Cicin

29年の経験
所在地: トルコ, イスタンブール

Dr. Irfan Cicin is a Professor of Medical Oncology at the Trakya University Faculty of Medicine (2015–present). He has over 20 years of medical oncology experience and has held academic roles since 2010.

Education: MD, Istanbul University – Cerrahpaşa (1991–1997). Residency in Internal Medicine, Trakya University (1997–2002). Fellowship in Medical Oncology, Trakya University (2002–2004).

Practice: Medical Oncologist, Trakya University (2005–2008). Medical Oncologist, Elazığ Training and Research Hospital (2008–2010). Associate Professor of Medical Oncology, Trakya University (2010–2015). He previously served as a physician in the Turkish Air Force at Etimesgut Military Hospital (2004–2005).

診察お問い合わせください
Medipol Acibadem District Hospital
Atakan Topcu

Atakan Topcu

13年の経験
クリニックは認証済み
Joint Commission International
所在地: トルコ, イスタンブール

Assoc. Prof. Atakan Topçu, M.D., is a medical oncologist at Medipol University and Medipol Acıbadem Regional Hospital. He treats solid tumors, including lung, breast, colorectal, gastric, and neuroendocrine cancers. His work also covers targeted therapies, immunotherapy, geriatric oncology, and cancer-related malnutrition, cachexia, and sarcopenia.

He has authored more than 50 peer-reviewed papers. Recent work includes a 2024 Frontiers in Medicine study on geriatric syndromes and a 2023 Future Oncology paper on sarcopenia and anxiety in lung cancer. He has also published on the CONUT score in breast cancer and on malnutrition in HER2-negative metastatic gastric cancer.

Dr. Topçu serves on the Editorial Board of BMC Cancer. He is a member of the Turkish Society of Medical Oncology, ESMO, and the Turkish Geriatrics Society. Education and training: M.D., Uludağ University; residency in Internal Medicine, Marmara University; fellowship in Medical Oncology, Bezmialem Vakıf University.

診察お問い合わせください
Istinye University Liv Hospital Bahcesehir
Seyda Gunduz

Seyda Gunduz

16年の経験
クリニックは認証済み
Best clinic for radiotherapy
Best price for PET/CT
Turkish Medical Association
所在地: トルコ, イスタンブール
診察お問い合わせください
Büyük Anadolu Hospitals (BAH International)
Volkan Kinas

Volkan Kinas

11年の経験
クリニックは認証済み
Turkish Medical Association
International Health Tourism Authorization Certificate
Turkish Medical Association (Türk Tabıplerı Bırliği)
所在地: トルコ, イスタンブール

Specializations

 

Cancer Surgery

Pancreatic Surgery

Bile Duct Surgery

Bariatric Metabolic Surgery

Oncological Surgery

Breast Surgery

Gastric cancer

Colon cancer

Thyroid Cancer

Obesity Surgery

Diabetes Surgeries

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

診察お問い合わせください
İstinye University Liv Hospital Topkapı
Muhammed Mustafa Atci

Muhammed Mustafa Atci

15年の経験
所在地: トルコ, イスタンブール

Dr. Muhammed Mustafa Atci is an Associate Professor of Medical Oncology at İstinye University, Liv Hospital Topkapı (2025–present). He previously served as Associate Professor and Education Coordinator at Prof. Dr. Cemil Taşcıoğlu City Hospital (2023–2025). He was also a Medical Oncologist there (2018–2021).

He has been a member of ASCO and the Turkish Society of Medical Oncology since 2018. He is the author or co-author of 19 peer-reviewed international papers on colon, breast, gastric, pancreatic, lung, thyroid, sarcoma, and colorectal cancers.

Notable works include a multicentre study on stage IIB colon cancer survival (Journal of Chemotherapy). He also studied the De Ritis ratio for lung metastasis in testicular cancer (Current Urology). His prognostic studies used PET/CT, MSI, lymph node ratio, and metabolic tumor volume.

診察お問い合わせください
Before and after gastric balloon at Klinik Mavi – 15 kg weight loss in 3 months result
Before and after gastric sleeve surgery at Klinik Mavi – 48 kg weight loss in 2 years result
Before and after gastric balloon at Klinik Mavi – visible weight loss results after 1 month
Before and after gastric sleeve surgery at Klinik Mavi – 52 kg weight loss in 24 months result
Before and after gastric sleeve surgery at Klinik Mavi – 37 kg weight loss in 6 months result
Before and after gastric sleeve surgery at Klinik Mavi – 37 kg weight loss in 6 months result
Before and after gastric balloon results at Klinik Mavi – 11 kg weight loss in 1 month
Muslum Tarkan

Muslum Tarkan

29年の経験
クリニックは認証済み
Turkish Medical Association
International Federation for the Surgery of Obesity and Metabolic Disorders Certificate
所在地: トルコ, エスキシェヒル
クリニック:Klinik Mavi
Dr. Muslum Tarkan is a specialist in bariatric surgery with over 15 years of experience. He is proficient in numerous operations including but not limited to lumpectomy, mastectomy, thyroid resection, removal of colon and liver cancer, and various types of gastric surgeries.
診察お問い合わせください
Emsey Hospital
Elnur Sahibov

Elnur Sahibov

10年の経験
クリニックは認証済み
The Baby-friendly Hospital Initiative (BFHI) by WHO and UNICEF
Turkish Medical Association
TEMOS International Healthcare Accreditation
+3
所在地: トルコ, イスタンブール
クリニック:
4.4
Emsey Hospital

Marmara University Faculty of Medicine, Department of Radiation Oncology Specialization training: 2012 -2016

Marmara University Faculty of Medicine (English) Undergraduate: 2004-2011

Sixteen Numbered Shirvan School (Azerbaijan) High School: 1998 -2004

診察お問い合わせください
Uniqacare Clinic
Hamza Ugur Bozbey

Hamza Ugur Bozbey

12年の経験
クリニックは認証済み
Turkish Medical Association
所在地: トルコ, イスタンブール
クリニック:Uniqacare Clinic
診察お問い合わせください
Medicana Bursa Hospital
Ahmet Cag Cal

Ahmet Cag Cal

38年の経験
所在地: トルコ, ブルサ
クリニック:
5.0
Medicana Bursa Hospital

経験

  • コンヤ セイディシェヒル ゲヴレクリ ヘルスセンター(必須サービス)(1988-1989)
  • アタテュルク ヘルスサイト アタテュルク州立病院 泌尿器科クリニック、専門学生 (1989-1991)
  • エーゲ大学医学部、泌尿器科学科、専門学生 (1991-1995)
  • メモリアル スローン ケタリングがんセンター、ニューヨーク、米国、オブザーバー (1993年9月-1994年1月)
  • エーゲ大学医学部、泌尿器科学科、泌尿器科医 (1995 – 2000)
  • メイヨークリニック 泌尿器科および研究室、ロチェスター、ミネソタ州、米国、オブザーバー (1997年10月-1998年1月)
  • カリフォルニア大学ロサンゼルス校、泌尿器科および免疫学-分子遺伝学科、ロサンゼルス、米国、研究助手 (2000年1月-5月)
  • エーゲ大学医学部、泌尿器科学科、泌尿器科医 (2000-2001)
  • エーゲ大学医学部、泌尿器科学科、M.D. 准教授 (2001-2007)
  • エーゲ大学医学部、泌尿器科学科、M.D. 医学教授 (2007-)
  • イズミル経済大学医学部、副学部長 (2012 – 2014)
  • メディカナ バーサ病院、泌尿器科、M.D. 医学教授 (2020-現在)
診察お問い合わせください
Medicana Sivas Hospital
Alandag Celal

Alandag Celal

17年の経験
所在地: トルコ, スィヴァス
クリニック:
5.0
Medicana Sivas Hospital
診察お問い合わせください
Private Koru Ankara Hospital
Emrah Eraslan

Emrah Eraslan

21年の経験
クリニックは認証済み
Turkish Medical Association
Joint Commission International
所在地: トルコ, アンカラ

Associate Professor Dr. Emrah Eraslan graduated from Ankara University Faculty of Medicine in 2005. From 2006 to 2011, he worked as a research assistant in the Department of Internal Medicine at Ankara University Faculty of Medicine and became an internal medicine specialist in 2011. Between 2011 and 2013, he worked as an internal medicine specialist and chief physician at Dr. Nafiz Körez Sincan State Hospital and Palu District State Hospital. From 2013 to 2016, he received medical oncology training at Dr. Abdurrahman Yurtaslan Ankara Oncology Education and Research Hospital and worked there until 2021. In 2023, he became an associate professor and contributed to his field with his publications throughout his career. He currently serves his patients at Koru Ankara Hospital. His medical interests include:

Breast Cancer

Prostate Cancer

Lung Cancer

Colorectal Cancer

Stomach Cancer

Ovarian Cancer

診察お問い合わせください
Medicana Sivas Hospital
Muhammed Gomec

Muhammed Gomec

17年の経験
所在地: トルコ, スィヴァス
クリニック:
5.0
Medicana Sivas Hospital
診察お問い合わせください
Medicana Bursa Hospital
Ersin Ozturk

Ersin Ozturk

28年の経験
所在地: トルコ, ブルサ
クリニック:
5.0
Medicana Bursa Hospital

メディカナブルサ病院病院部門 一般外科 学位 M.D. 医学教授 医師名 エルシン・オズチュルク、M.D. 医学教授 卒業教育 イスタンブール大学ジェラパシャ医学部(1985-1992)大学院教育(研修医) ウルダ大学医学部、一般外科レジデンシープログラム(2000-2005) ウルダ大学大学院科学部、生理学 Ph.D.、(2005–2009)

専門分野 一般外科

一般外科

外科的腫瘍学

生理学

消化器外科

外科的腫瘍学

腹腔鏡手術

肥満手術

ヘルニア手術

肛門学

経験 ウルダ大学医学部(2005-2009)

ウルダ大学大学院科学部、生理学部(2005-2009)

研究フェローシップ、クリーブランドクリニック財団 大腸直腸外科部門、クリーブランド、オハイオ州、アメリカ 合衆国(2008–2009)

ウルダ大学医学部、一般外科部門、M.D. 医学助教授 (2009-2011)

ウルダ大学医学部、一般外科部門、M.D. 准教授 医学教授 (2011-2019)

KTOカラタユ大学医学部、一般外科部門、医学教授 (2019)

メディカナブルサ病院、一般外科部門、M.D. 医学教授 (2019-present)

診察お問い合わせください
Medicana Bursa Hospital
Kayihan Engin

Kayihan Engin

41年の経験
所在地: トルコ, ブルサ
クリニック:
5.0
Medicana Bursa Hospital

教育経験

  • アメリカン・ロバート・カレッジ、イスタンブル、トルコ (1973-1977)
  • ウルダ大学医学部、医学のディプロマ、ブルサ、トルコ (1983)
  • 国立がん研究所、N.C.I、N.I.H 研究奨学金、「職業曝露とがんリスク」 ベセスダ、MD、米国 (1989)
  • オンコロジー・核医学センター、 放射線腫瘍学研修医、イスタンブル、トルコ 専門認定証 (1990)
  • トーマス・ジェファーソン大学、博士後研究フェローシップ、サーモラジオセラピー学部放射線腫瘍学科 フィラデルフィア、PA、米国 (1990-1994)

経験

  • パザルヨル・メディカル・ハウス、義務奉仕 イスピル、エルズルム、トルコ (1985-1986)
  • 国立がん研究所、N.C.I、N.I.H 研究奨学金「職業曝露とがんリスク」 ベセスダ、MD、米国 (1989)
  • オンコロジー・核医学センター、放射線腫瘍学研修医 イスタンブル、トルコ 専門認定証 (1990)
  • トーマス・ジェファーソン大学、博士後研究フェローシップ サーモラジオセラピー学部放射線腫瘍学科 フィラデルフィア、PA、米国 (1990-1994)
  • ウルダ大学医学部 (1991-2005) 教授 (1999-2005) & 学部長 (1994-2005) 放射線腫瘍学科 ブルサ、トルコ
  • ウルダ大学医学部、学部認定コーディネーター ブルサ、トルコ (2001-2004)
  • アナドルメディカルセンター、教授 & 放射線腫瘍学科長 イスタンブル、トルコ (2004-2017)
  • アナドルメディカルセンター、腫瘍科学コーディネーター イスタンブル、トルコ (2011-2017)
  • ジェイラン国際病院、腫瘍科学ディレクター ブルサ、トルコ (2017-2018)
  • メディカナ・ブルサ病院、腫瘍科学ディレクター ブルサ、トルコ (2018-現在)
診察お問い合わせください

41名の医師のうち20名をご覧いただきました

海外のクリニックを選ぶことはストレスフルです。800,000名以上の患者をサポートしたBookimedは、お客様の懸念を理解しています。信頼できる医師、最高の価格品質オプション、複雑なケースの解決策を見つける方法を知っています。すべての段階でお客様をご案内いたします。

ヤン・マツィイフスキー

医療コーディネーターチーム責任者

4300+件以上の患者の旅をガイド

Bookimedで3

Turkeyの278名の患者が今月当社を通じて医師を見つけました

完璧な医師マッチングを取得する方法

1

2分のクイズ

目標、予算、スケジュールをお聞かせください

2

人間のマッチング + AI

アルゴリズムがマッチングを見つけ、コーディネーターが適合性を確認します

3

オプション準備完了

価格、パッケージ、日程を比較。コーディネーターとチャット

選択肢に迷っていますか?

専属の Bookimedコーディネーターがお客様のニーズに合わせた完璧な外科医を見つけるお手伝いをします

  • すべての段階で24時間365日サポート
  • 医師とのマッチングサポートとクリニックとの全てのコミュニケーションを処理
  • 旅行、宿泊、送迎を調整します

治療をガイド

医療訓練を受けた専属コーディネーター

Peguy Beaugris
Tetyana Hyrych
Zekra Eldeeb
Victoria Olayinka
Iryna Sydorchuk
Tetiana Ihnatiuk

適切な医師とクリニックの選び方:内部者のヒント

医師やクリニックを選ぶ際は、これらの重要なポイントを覚えておいてください:
資格を確認
ISAPS、JCI、または関連医学会などの機関からの認証を確認してください
成功率を確認
お客様の特定治療に豊富な経験と実績のある医師をお選びください
患者レビューを読む
実際の患者様のBookimedレビューをご覧になり、体験について学んでください
効果的なコミュニケーションの確保
円滑な治療のため言語サポートを提供するクリニックを選んでください。
サービスについて質問
隠れた費用を避けるため、価格に宿泊、現地送迎、アフターケアなどのサービスが含まれているかご確認ください

Bookimed洞察:トルコのトップ膵神経内分泌腫瘍専門家(2026)

Bookimedはトルコの膵神経内分泌腫瘍治療リクエスト2件を調整し、41名のトップ評価専門家と協力しています。この表の医師は国際的資格、臨床専門知識、患者の結果に基づいて選ばれています。2026年ランキングは実際の患者ケースとパートナークリニックの現行プログラムからの検証済みデータを使用して形成されています
順位医師経験適合する方特色クリニックと所在地診察